EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis
| Autor: | Chuang Zhong Deng, Kai Yao, Li Juan Jiang, Qiang Hua Zhou, Zai Shang Li, Sheng Jie Guo, Kang bo Huang, Zhuo Wei Liu, Qi Hua Peng, Hui Han, Yong Hong Li, Ranyi Liu, Ting Yu Liu, Fangjian Zhou, Zi Ke Qin |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Urology medicine.medical_treatment 030232 urology & nephrology Salvage therapy Gene mutation medicine.disease_cause 03 medical and health sciences 0302 clinical medicine CDKN2A Internal medicine medicine Humans Penile cancer Nimotuzumab Epidermal growth factor receptor Neoplasm Metastasis Penile Neoplasms Aged Salvage Therapy Chemotherapy biology business.industry Middle Aged medicine.disease ErbB Receptors 030220 oncology & carcinogenesis biology.protein Female KRAS business medicine.drug |
| Zdroj: | Urologic Oncology: Seminars and Original Investigations. 37:71-77 |
| ISSN: | 1078-1439 |
| Popis: | Purpose There are limited therapeutic options for patients with advanced penile squamous cell carcinoma (PSCC) after chemotherapy failure. Thus, we evaluated the feasibility of salvage treatment using the epidermal growth factor receptor (EGFR) mono-antibody nimotuzumab in chemotherapy-failed PSCC patients and explored potential response or resistance biomarkers. Materials and methods Six chemotherapy-failed PSCC patients with locally advanced disease or distant metastasis were enrolled consecutively to nimotuzumab treatment. Clinical responses and side effects were evaluated, and genetic characteristics of cancer specimens were analyzed through the next-generation sequencing of hotspot regions in cancer-related genes. Results Two of 6 patients showed partial responses, one was identified as having stable disease, while the other 3 had disease progression after nimotuzumab therapy. Side effects were all welltolerated. Genetic analysis revealed that TP53, CDKN2A, RB1, SMAD4, FLT3, and PIK3CA were the most frequently mutated genes in PSCC specimens, while altered KRAS, HRAS, EGFR, ERBB2, and FLT3 may be correlated with nimotuzumab resistance. Furthermore, 3 patients that were human papillomavirus-positive each showed clinical response or stable disease. Conclusions EGFR mono-antibody may be a potential modality for locally advanced PSCC patients after chemotherapy failure. Further large-scale clinical studies are needed to elucidate the role of human papillomavirus status and critical gene mutations in the clinical response to EGFR-targeted therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect